Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Schneider

Interventional Pain Medicine Havre De Grace, MD Medical Doctor

NPI 1700032711 CMS profile 121995

253 Lewis Ln Ste 302, Havre De Grace, MD 21078

Open in the dashboard

General payments

$9,285

486 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Schneider of Havre De Grace, MD is reported in the CMS Open Payments database as having received $9,285 across 486 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,173 66
2024 General $1,889 86
2023 General $1,461 71
2022 General $711 40
2021 General $298 17
2020 General $1,095 51
2019 General $2,658 155

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Schneider
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jeffrey Schneider were reported at $1,173. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jeffrey Schneider Interventional Pain Medicine median Middle half National median
2019 $2,658 $684 $216–$2,079 $163
2020 $1,095 $382 $122–$1,109 $114
2021 $298 $552 $167–$1,554 $132
2022 $711 $605 $187–$1,924 $149
2023 $1,461 $671 $195–$1,915 $160
2024 $1,889 $684 $206–$1,837 $164
2025 $1,173 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,850 114 payments
  2. Abbott Laboratories $850 28 payments
  3. Pfizer Inc. $837 51 payments
  4. Lundbeck LLC $528 20 payments
  5. Averitas Pharma Inc. $417 15 payments
  6. Collegium Pharmaceutical, Inc. $394 21 payments
  7. Flexion Therapeutics, Inc. $335 12 payments
  8. Vertos Medical, Inc. $288 28 payments
  9. Nalu Medical, Inc. $282 23 payments
  10. Boston Scientific Corporation $224 11 payments
  11. Other $3,280 163 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,285 486 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,036 65 payments
  2. QULIPTA $938 69 payments
  3. Proclaim Family of SCS IPGs $542 13 payments
  4. NURTEC ODT $530 27 payments
  5. VYEPTI $528 20 payments
  6. Qutenza $441 16 payments
  7. Zilretta $335 12 payments
  8. XTAMPZA $325 18 payments
  9. LYRICA $292 23 payments
  10. BOTOX $286 16 payments
  11. Other $5,678 309 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

442

Median for Anesthesiology: 322

Drug cost

$8,548

Median for Anesthesiology: $8,738

Branded share of claims

20.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 14 $3,390
Pregabalin Generic 85 $1,268
Oxycodone Hcl Generic 80 $978
Gabapentin Generic 58 $768
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 26 $682
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $408
Morphine Sulfate Er Morphine Sulfate Brand 25 $346
Tramadol Hcl Generic 35 $196
Diclofenac Sodium Generic 24 $178
Buspirone Hcl Generic 18 $156

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$401,551

Of which drugs: $48,578

Medicare patients

464

Average age 74

Services billed

16,388

273 women, 191 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Ischemic heart disease 30%
COPD 24%
Depression 24%
Chronic kidney disease 23%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 30 1,602 $22,163
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 19 1,450 $8,381
Injection, methylprednisolone acetate, 1 mg J1010 Office 79 4,303 $429
Injection, methylprednisolone acetate, 40 mg J1030 Office 29 31 $136

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
  • Lundbeck LLC $217
$217 — —
QULIPTA
  • AbbVie, Inc. $180
$180 — —
Qutenza
  • Averitas Pharma Inc. $176
$176 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $153
$153 — —
NURTEC ODT
  • PFIZER INC. $127
$127 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

486 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record